Aveo stock plunges after delay in FDA approval submission for cancer drug
January 31, 2019 at 11:01 AM EST
Shares of Cambridge biotech Aveo Oncology fell by more than half on Thursday after it announced it had once again received pushback from the FDA over its kidney cancer drug.
